L
Liliana Bordeianou
Researcher at Harvard University
Publications - 203
Citations - 4539
Liliana Bordeianou is an academic researcher from Harvard University. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 33, co-authored 181 publications receiving 3294 citations. Previous affiliations of Liliana Bordeianou include Boston Children's Hospital & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From the American Society of Colon and Rectal Surgeons and Society of American Gastrointestinal and Endoscopic Surgeons.
Joseph C. Carmichael,Deborah S. Keller,Gabriele Baldini,Liliana Bordeianou,Eric G. Weiss,Lawrence Lee,Marylise Boutros,James McClane,Liane S. Feldman,Scott R. Steele +9 more
TL;DR: This clinical practice guideline represents a collaborative effort between the American Society of Colon and Rectal Surgeon (ASCRS) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).
Journal ArticleDOI
Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications
Hiroko Kunitake,Richard A. Hodin,Paul C. Shellito,Bruce E. Sands,Joshua R. Korzenik,Liliana Bordeianou +5 more
TL;DR: A large patient cohort is examined to clarify whether a relationship exists between IFX and postoperative complications in surgical patients with Crohn’s disease and ulcerative colitis, and to assess the impact of IFX, as well as other potential risk factors, on the rates of cumulative postoperative infections.
Journal ArticleDOI
Cystic Pancreatic Endocrine Neoplasms: A Distinct Tumor Type?
Liliana Bordeianou,Parsia A. Vagefi,Dushyant V. Sahani,Vikram Deshpande,Elena Y. Rakhlin,Andrew L. Warshaw,Carlos Fernandez-del Castillo +6 more
TL;DR: CPENs are larger and more likely to be symptomatic then solid PENs, suggesting they may be a distinct tumor type, and should be included in the differential of the cystic lesions of the pancreas.
Journal ArticleDOI
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Aparna Raj Parikh,Emily E. Van Seventer,Giulia Siravegna,Anna Hartwig,Ariel Jaimovich,Yupeng He,Katie Kanter,Madeleine Fish,Kathryn Fosbenner,Benchun Miao,Susannah T. Phillips,John H. Carmichael,Nihaarika Sharma,Joy X. Jarnagin,Islam Baiev,Yojan S. Shah,Isobel J Fetter,Heather A. Shahzade,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Jon Dubois,Joseph W. Franses,Bruce J. Giantonio,Lipika Goyal,Samuel J. Klempner,Ryan D. Nipp,Eric Roeland,David P. Ryan,Colin D. Weekes,Jennifer Y. Wo,Theodore S. Hong,Liliana Bordeianou,Cristina R. Ferrone,Motaz Qadan,Hiroko Kunitake,David H. Berger,Rocco Ricciardi,James C. Cusack,Victoria M. Raymond,AmirAli Talasaz,Genevieve M. Boland,Ryan B. Corcoran +42 more
TL;DR: Benton et al. as mentioned in this paper evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection, which demonstrated favorable sensitivity and specificity for recurrence.
Journal ArticleDOI
A pilot study of natural orifice transanal endoscopic total mesorectal excision with laparoscopic assistance for rectal cancer.
Patricia Sylla,Liliana Bordeianou,David H. Berger,Kyung Su Han,Gregory Y. Lauwers,Dushyant V. Sahani,Mohammed A. Sbeih,Antonio M. Lacy,David W. Rattner +8 more
TL;DR: In this pilot study of five patients with rectal cancer, transanal endoscopic TME with laparoscopic assistance is feasible and safe, and is a promising alternative to open and laparoscope TME.